Search research articles
Contact Us
Filters
Showing results (21-30 of 33) with videos related to
Page
of 4
Sort By:
Journal of Proteome Research
|
June 16, 2009
Mass spectrometry (LC-MS/MS) site-mapping of N-glycosylated membrane proteins for breast cancer biomarkers
Stephen A Whelan, Ming Lu, Jianbo He, et al.
Journal of Proteome Research
|
September 1, 2012
Mass spectrometry (LC-MS/MS) identified proteomic biosignatures of breast cancer in proximal fluid
Stephen A Whelan, Jianbo He, Ming Lu, et al.
Human Pathology
|
September 5, 2006
Decreased expression of annexin A1 is correlated with breast cancer development and progression as determined by a tissue microarray analysis
Dejun Shen, Farzad Nooraie, Yahya Elshimali, et al.
Oncotarget
|
April 19, 2017
CD24 Expression and differential resistance to chemotherapy in triple-negative breast cancer
Xinyu Deng, Sophia Apple, Hong Zhao, et al.
International Journal of Oncology
|
December 5, 2006
Detection of breast cancer biomarkers in nipple aspirate fluid by SELDI-TOF and their identification by combined liquid chromatography-tandem mass spectrometry
Jianbo He, Jeffrey Gornbein, Dejun Shen, et al.
International Journal of Proteomics
|
November 24, 2011
Proteomic-based biosignatures in breast cancer classification and prediction of therapeutic response
Jianbo He, Stephen A Whelan, Ming Lu, et al.
Biochemical and Biophysical Research Communications
|
November 30, 2004
Loss of annexin A1 expression in human breast cancer detected by multiple high-throughput analyses
Dejun Shen, Helena R Chang, Zugen Chen, et al.
Human Pathology
|
November 17, 2010
Higher levels of GATA3 predict better survival in women with breast cancer
Nam K Yoon, Erin L Maresh, Dejun Shen, et al.
Oncotarget
|
November 5, 2016
ERBB2 mutation is associated with a worse prognosis in patients with CDH1 altered invasive lobular cancer of the breast
Zheng Ping, Gene P Siegal, Shuko Harada, et al.
Cancer Research Communications
|
August 25, 2023
A Pilot Study of Neoadjuvant Nivolumab, Ipilimumab, and Intralesional Oncolytic Virotherapy for HER2-negative Breast Cancer
Vina P Nguyen, Katie M Campbell, Theodore S Nowicki, et al.
Page
of 4
Search research articles
Search
Showing results (21-30 of 33) with videos related to
Sort By:
Page
of 4
Journal of Proteome Research
|
June 16, 2009
Mass spectrometry (LC-MS/MS) site-mapping of N-glycosylated membrane proteins for breast cancer biomarkers
Stephen A Whelan, Ming Lu, Jianbo He, et al.
Journal of Proteome Research
|
September 1, 2012
Mass spectrometry (LC-MS/MS) identified proteomic biosignatures of breast cancer in proximal fluid
Stephen A Whelan, Jianbo He, Ming Lu, et al.
Human Pathology
|
September 5, 2006
Decreased expression of annexin A1 is correlated with breast cancer development and progression as determined by a tissue microarray analysis
Dejun Shen, Farzad Nooraie, Yahya Elshimali, et al.
Oncotarget
|
April 19, 2017
CD24 Expression and differential resistance to chemotherapy in triple-negative breast cancer
Xinyu Deng, Sophia Apple, Hong Zhao, et al.
International Journal of Oncology
|
December 5, 2006
Detection of breast cancer biomarkers in nipple aspirate fluid by SELDI-TOF and their identification by combined liquid chromatography-tandem mass spectrometry
Jianbo He, Jeffrey Gornbein, Dejun Shen, et al.
International Journal of Proteomics
|
November 24, 2011
Proteomic-based biosignatures in breast cancer classification and prediction of therapeutic response
Jianbo He, Stephen A Whelan, Ming Lu, et al.
Biochemical and Biophysical Research Communications
|
November 30, 2004
Loss of annexin A1 expression in human breast cancer detected by multiple high-throughput analyses
Dejun Shen, Helena R Chang, Zugen Chen, et al.
Human Pathology
|
November 17, 2010
Higher levels of GATA3 predict better survival in women with breast cancer
Nam K Yoon, Erin L Maresh, Dejun Shen, et al.
Oncotarget
|
November 5, 2016
ERBB2 mutation is associated with a worse prognosis in patients with CDH1 altered invasive lobular cancer of the breast
Zheng Ping, Gene P Siegal, Shuko Harada, et al.
Cancer Research Communications
|
August 25, 2023
A Pilot Study of Neoadjuvant Nivolumab, Ipilimumab, and Intralesional Oncolytic Virotherapy for HER2-negative Breast Cancer
Vina P Nguyen, Katie M Campbell, Theodore S Nowicki, et al.
Page
of 4